Pemov, A., Hansen, N. F., Sindiri, S., Patidar, R., Higham, C. S., Dombi, E., Miettinen, M. M., Fetsch, P., Brems, H., Chandrasekharappa, S. C., Jones, K., Zhu, B., Wei, J. S., , , , , Mullikin, J. C., Wallace, M. R., Khan, J., Legius, E., Widemann, B. C., & Stewart, D. R. (2019). low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromas. Neuro-oncology, 21(8), 981–992. http://access.bl.uk/ark:/81055/vdc_100092354713.0x00001b